Literature DB >> 3064606

Emerging benefits of angiotensin converting enzyme inhibitors versus other antihypertensive agents.

J A Schoenberger1.   

Abstract

The benefit of treatment of mild to moderate hypertension is minimal over the short term. Hence, sustained control of high blood pressure over many years is required. Under these circumstances, the adverse effects of conventional antihypertensive therapy with diuretics and beta-blockers assume great importance, especially hypokalemia and alterations in blood lipid levels. These metabolic changes can negate the benefit of lowered blood pressure. The adverse effects of antihypertensive drugs, especially on the quality of life of hypertensive patients, have recently received a great deal of attention. Angiotensin converting enzyme inhibitors are free of these adverse effects and may actually enhance the quality of life. They are effective antihypertensive agents when given in low doses, they can often be given once a day, and they are effective in all age groups. Combined with a diuretic they are effective in black and elderly hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3064606     DOI: 10.1016/0002-9343(88)90467-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

Review 1.  Cilazapril. A review.

Authors:  T Szucs
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 2.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 3.  ACE inhibitors for the treatment of myocardial ischemia?

Authors:  C Linder; G Heusch
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

4.  Controversies in the use of combination therapy in the older patient.

Authors:  J A Schoenberger
Journal:  Drugs       Date:  1990       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.